GlassScriptPhysician profile
William David Birenbaum
NPI 1407876550
$2,752.90
in general payments reported to CMS, 2019-2025
29 companies · $18.81 in 2025
The $18.81 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $975 · 2020: $543 · 2021: $251 · 2022: $13.05 · 2023: $374 · 2024: $577 · 2025: $18.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $970.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $334.68 | 2021-2024 | Ubrelvy, Vraylar |
| Pfizer INC. | $321.93 | 2019-2025 | |
| Lilly USA, LLC | $225.10 | 2019-2024 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $202.09 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $167.45 | 2019-2024 | Xifaxan |
| Novo Nordisk INC | $163.18 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $145.69 | 2019-2024 | Eliquis |
| Amgen INC. | $143.81 | 2019-2024 | Evenity, Otezla, Repatha |
| Abbott Laboratories | $130.95 | 2019-2023 | Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $111.85 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $111.24 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $82.09 | 2019-2024 | Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $77.93 | 2019-2024 | Xarelto |
| Allergan, INC. | $74.70 | 2020 | |
| Merck Sharp & Dohme LLC | $64.66 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $51.47 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.69 | 2023-2024 | |
| Sunovion Pharmaceuticals INC. | $44.46 | 2019 | |
| Astellas Pharma US INC | $41.02 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.75 | 2019 | |
| Janssen Biotech, INC. | $30.53 | 2019 | |
| Corcept Therapeutics | $25.69 | 2024 | Korlym |
| Lundbeck LLC | $23.47 | 2024 | Rexulti |
| Esperion Therapeutics, INC. | $20.53 | 2024 | Nexletol |
| Sumitomo Pharma America, INC. | $19.91 | 2023 | Gemtesa |
| Amarin Pharma, INC. | $17.03 | 2020 | |
| Exact Sciences Corporation | $14.19 | 2023 | Cologuard Collection Kit |
| Insulet Corporation | $11.31 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Birenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.